Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of secretory phospholipase A2. 1-design, synthesis and structure-activity relationship studies starting from 4-tetradecyloxybenzamidine to obtain specific inhibitors of group II sPLA2s.
Assogba L, Ahamada-Himidi A, Habich NM, Aoun D, Boukli L, Massicot F, Mounier CM, Huet J, Lamouri A, Ombetta JE, Godfroid JJ, Dong CZ, Heymans F. Assogba L, et al. Among authors: lamouri a. Eur J Med Chem. 2005 Sep;40(9):850-61. doi: 10.1016/j.ejmech.2005.03.027. Eur J Med Chem. 2005. PMID: 16084626
Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
Serradji N, Martin M, Bensaid O, Cisternino S, Rousselle C, Dereuddre-Bosquet N, Huet J, Redeuilh C, Lamouri A, Dong CZ, Clayette P, Scherrmann JM, Dormont D, Heymans F. Serradji N, et al. Among authors: lamouri a. J Med Chem. 2004 Dec 2;47(25):6410-9. doi: 10.1021/jm040860g. J Med Chem. 2004. PMID: 15566310
Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines.
Boukli L, Touaibia M, Meddad-Belhabich N, Djimdé A, Park CH, Kim JJ, Yoon JH, Lamouri A, Heymans F. Boukli L, et al. Among authors: lamouri a. Bioorg Med Chem. 2008 Feb 1;16(3):1242-53. doi: 10.1016/j.bmc.2007.10.077. Epub 2007 Nov 13. Bioorg Med Chem. 2008. PMID: 17993277
Design of new potent and selective secretory phospholipase A(2) inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives.
Meddad-Belhabich N, Aoun D, Djimdé A, Redeuilh C, Dive G, Massicot F, Chau F, Heymans F, Lamouri A. Meddad-Belhabich N, et al. Among authors: lamouri a. Bioorg Med Chem. 2010 May 15;18(10):3588-600. doi: 10.1016/j.bmc.2010.03.049. Epub 2010 Mar 27. Bioorg Med Chem. 2010. PMID: 20417107 Free article.
Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity.
Serradji N, Bensaid O, Martin M, Sallem W, Dereuddre-Bosquet N, Benmehdi H, Redeuilh C, Lamouri A, Dive G, Clayette P, Heymans F. Serradji N, et al. Among authors: lamouri a. Bioorg Med Chem. 2006 Dec 1;14(23):8109-25. doi: 10.1016/j.bmc.2006.07.031. Epub 2006 Aug 8. Bioorg Med Chem. 2006. PMID: 16893650 Free article.
Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines.
Rondu F, Le Bihan G, Wang X, Lamouri A, Touboul E, Dive G, Bellahsene T, Pfeiffer B, Renard P, Guardiola-Lemaitre B, Manechez D, Penicaud L, Ktorza A, Godfroid JJ. Rondu F, et al. Among authors: lamouri a. J Med Chem. 1997 Nov 7;40(23):3793-803. doi: 10.1021/jm9608624. J Med Chem. 1997. PMID: 9371245 Free article.
45 results